贝利尤单抗治疗难治性和进行性皮肤红斑狼疮：一项回顾性单中心研究
[Resistant and progressive cutaneous lupus erythematosus treated with belimumab: A retrospective monocentric study].
作者信息
Dresco F, Puzenat E, Delobeau M, Salard D, Lihoreau T, Pelletier F, Aubin F
机构信息
Service de dermatologie, UMR Inserm 1098, CHU et université de Franche Comté, Besançon, France.
Service de dermatologie, centre hospitalier de Haute Comté, Pontarlier, France.
出版信息
Rev Med Interne. 2020 Mar;41(3):152-159. doi: 10.1016/j.revmed.2019.12.004. Epub 2020 Jan 21.
BACKGROUND
Belimumab is currently approved for the treatment of active systemic lupus erythematosus (SLE). The aim of our study was to evaluate the efficacy of belimumab in the treatment of cutaneous lupus erythematosus (CLE), resistant to conventional therapy.
PATIENTS AND METHODS
Seven patients with resistant and progressive LEC and treated with belimumab were retrospectively analyzed. The efficacy and safety of belimumab were evaluated with the CLASI, RCLASI and DLQI scores, after 6 to 12 months of treatment.
RESULTS
Eighty-three percent of patients demonstrated a significant clinical improvement based on the CLASI and RCLASI activity scores, including 1 complete and 4 partial responses, without worsening of CLASI and RCLASI damage scores. Eighty percent of patients also showed an improvement of their quality of life (DLQI). Oral corticosteroids were discontinued in all patients. Tolerance was acceptable with only one serious adverse event (bacteriema).
CONCLUSION
Our study suggests the clinical efficiency of belimumab in a series of 7 patients presenting a resistant and progressive CLE.
背景
贝利尤单抗目前已被批准用于治疗活动性系统性红斑狼疮（SLE）。我们研究的目的是评估贝利尤单抗治疗对传统治疗耐药的皮肤红斑狼疮（CLE）的疗效。
患者与方法
对7例接受贝利尤单抗治疗的耐药且病情进展的红斑狼疮患者进行回顾性分析。在治疗6至12个月后，采用CLASI、RCLASI和DLQI评分评估贝利尤单抗的疗效和安全性。
结果
根据CLASI和RCLASI活动评分，83%的患者表现出显著的临床改善，包括1例完全缓解和4例部分缓解，且CLASI和RCLASI损伤评分未恶化。80%的患者生活质量（DLQI）也有所改善。所有患者均停用了口服糖皮质激素。耐受性良好，仅发生1例严重不良事件（菌血症）。
结论
我们的研究表明，贝利尤单抗对7例耐药且病情进展的CLE患者具有临床疗效。
Zotero 插件